Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men

Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of... Clin Drug Investig (2017) 37:873–879 DOI 10.1007/s40261-017-0547-7 ORIGINAL RESEARCH ARTICLE Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men 1 1 1,2 1 ˚ • • • • Hakan Olsson Niclas Petri Lars Erichsen Anders Malmberg Lars Grundemar Published online: 28 June 2017 The Author(s) 2017. This article is an open access publication Abstract Results Time-matched, one-sided 95% upper confidence Background and Objectives Degarelix is a gonadotropin- boundaries for baseline-corrected average changes from releasing hormone antagonist registered for the treatment placebo for the QT interval, corrected using the Fridericia of advanced hormone-dependent prostate cancer. Treat- method (DDQTcF), did not exceed 10 ms at any timepoint, ment causing androgen deprivation is associated with QT with maximum degarelix concentrations reaching approx- prolongation and this study investigated whether degarelix imately threefold the concentrations seen in the treatment at supratherapeutic concentrations has an intrinsic effect of prostate cancer. Furthermore, concentration-exposure per se on cardiac repolarisation and the QT interval. analysis indicated absence of any QT prolongation effects Methods This was a single-centre, randomised, crossover of degarelix. No significant effect on any http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Drug Investigation Springer Journals

Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men

Loading next page...
 
/lp/springer_journal/effect-of-degarelix-a-gonadotropin-releasing-hormone-receptor-TllYK0AAtw
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
1173-2563
eISSN
1179-1918
D.O.I.
10.1007/s40261-017-0547-7
Publisher site
See Article on Publisher Site

Abstract

Clin Drug Investig (2017) 37:873–879 DOI 10.1007/s40261-017-0547-7 ORIGINAL RESEARCH ARTICLE Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men 1 1 1,2 1 ˚ • • • • Hakan Olsson Niclas Petri Lars Erichsen Anders Malmberg Lars Grundemar Published online: 28 June 2017 The Author(s) 2017. This article is an open access publication Abstract Results Time-matched, one-sided 95% upper confidence Background and Objectives Degarelix is a gonadotropin- boundaries for baseline-corrected average changes from releasing hormone antagonist registered for the treatment placebo for the QT interval, corrected using the Fridericia of advanced hormone-dependent prostate cancer. Treat- method (DDQTcF), did not exceed 10 ms at any timepoint, ment causing androgen deprivation is associated with QT with maximum degarelix concentrations reaching approx- prolongation and this study investigated whether degarelix imately threefold the concentrations seen in the treatment at supratherapeutic concentrations has an intrinsic effect of prostate cancer. Furthermore, concentration-exposure per se on cardiac repolarisation and the QT interval. analysis indicated absence of any QT prolongation effects Methods This was a single-centre, randomised, crossover of degarelix. No significant effect on any

Journal

Clinical Drug InvestigationSpringer Journals

Published: Jun 28, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off